{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:25:14Z","timestamp":1791645914996,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA283805"],"award-info":[{"award-number":["R50CA283805"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA243072"],"award-info":[{"award-number":["U01CA243072"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F30CA277965"],"award-info":[{"award-number":["F30CA277965"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007439"],"award-info":[{"award-number":["T32HL007439"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["ZIA HL006163"],"award-info":[{"award-number":["ZIA HL006163"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012431","name":"Celldex Therapeutics","doi-asserted-by":"publisher","award":["CDX-1401\/poly-ICLC"],"award-info":[{"award-number":["CDX-1401\/poly-ICLC"]}],"id":[{"id":"10.13039\/100012431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007170"],"award-info":[{"award-number":["T32GM007170"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006398","name":"Roswell Park Alliance Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008209","name":"University at Buffalo","doi-asserted-by":"publisher","award":["UL1TR001412"],"award-info":[{"award-number":["UL1TR001412"]}],"id":[{"id":"10.13039\/100008209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100106","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:12:46Z","timestamp":1745583166000},"page":"100106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Checkpoint immunotherapy is associated with preferential activation of tumor antigen\u2013specific CD4+ T cells in MDS"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-8248","authenticated-orcid":false,"given":"Elizabeth A.","family":"Griffiths","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-6488","authenticated-orcid":false,"given":"Eduardo Cortes","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-1234","authenticated-orcid":false,"given":"Junko","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4444-7651","authenticated-orcid":false,"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-9354","authenticated-orcid":false,"given":"Laura W.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devdeep","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-8067","authenticated-orcid":false,"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3919-3914","authenticated-orcid":false,"given":"Shovik","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5567","authenticated-orcid":false,"given":"Kai","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher M.","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Kuechle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-0409","authenticated-orcid":false,"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4247-8593","authenticated-orcid":false,"given":"Michael J.","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bneo.2025.100106_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00277-016-2649-3","article-title":"Causes of death in 2877 patients with myelodysplastic syndromes","volume":"95","author":"Nachtkamp","year":"2016","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100106_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100106_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100106_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.seminoncol.2011.04.011","article-title":"Failure of hypomethylating agent-based therapy in myelodysplastic syndromes","volume":"38","author":"Kadia","year":"2011","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100106_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","article-title":"Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation","volume":"131","author":"Zeidan","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100106_bib6","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2016.150714","article-title":"Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS Consortium scoring system","volume":"101","author":"Prebet","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bneo.2025.100106_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","article-title":"The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells","volume":"34","author":"Almstedt","year":"2010","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.bneo.2025.100106_bib8","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100106_bib9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00262-011-1024-4","article-title":"Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine","volume":"60","author":"Yan","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.bneo.2025.100106_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","article-title":"Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer","volume":"2","author":"Odunsi","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.bneo.2025.100106_bib11","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.leukres.2014.09.001","article-title":"Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts","volume":"38","author":"Srivastava","year":"2014","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.bneo.2025.100106_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/15592294.2015.1017198","article-title":"Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts","volume":"10","author":"Srivastava","year":"2015","journal-title":"Epigenetics"},{"issue":"11","key":"10.1016\/j.bneo.2025.100106_bib13","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.18632\/oncotarget.7326","article-title":"Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy","volume":"7","author":"Srivastava","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bneo.2025.100106_bib14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bneo.2025.100106_bib15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.bneo.2025.100106_bib16","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1158\/0008-5472.CAN-17-3953","article-title":"Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res"},{"issue":"7577","key":"10.1016\/j.bneo.2025.100106_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.bneo.2025.100106_bib18","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100106_bib19","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2025.100106_bib20","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"\u00d8rskov","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bneo.2025.100106_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.bneo.2025.100106_bib22","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/bloodadvances.2021004583","article-title":"Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy","volume":"5","author":"Abbas","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2025.100106_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2025.100106_bib24","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bneo.2025.100106_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101222","article-title":"Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: what have we learned so far and where are we heading?","volume":"33","author":"Bewersdorf","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100106_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/imt.13.51","article-title":"Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy","volume":"5","author":"Kerkhoff","year":"2013","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.bneo.2025.100106_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"10.1016\/j.bneo.2025.100106_bib28","first-page":"6076","article-title":"NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer","volume":"63","author":"Odunsi","year":"2003","journal-title":"Cancer Res"},{"issue":"31","key":"10.1016\/j.bneo.2025.100106_bib29","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.1073\/pnas.0703342104","article-title":"Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T cell responses in ovarian cancer","volume":"104","author":"Odunsi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.bneo.2025.100106_bib30","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-17-1792","article-title":"NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome","volume":"24","author":"Griffiths","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2025.100106_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100106_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2017.03.509","article-title":"NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer","volume":"145","author":"Szender","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100106_bib33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100106_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","article-title":"Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage","volume":"20","author":"Aran","year":"2019","journal-title":"Nat Immunol"},{"issue":"43","key":"10.1016\/j.bneo.2025.100106_bib35","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"232","key":"10.1016\/j.bneo.2025.100106_bib36","doi-asserted-by":"crossref","first-page":"232ra51","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.bneo.2025.100106_bib37","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.4049\/jimmunol.1000808","article-title":"Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity","volume":"186","author":"Tsuji","year":"2011","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100106_bib38","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100106_bib39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100106_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30755-0","article-title":"Comparison of methods and resources for cell-cell communication inference from single-cell RNA-seq data","volume":"13","author":"Dimitrov","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bneo.2025.100106_bib41","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1038\/s41375-020-0765-5","article-title":"Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells","volume":"34","author":"Srivastava","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bneo.2025.100106_bib42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bneo.2025.100106_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti\u2013PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.bneo.2025.100106_bib44","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer\u2013dendritic cell axis defines checkpoint therapy\u2013responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.bneo.2025.100106_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer","volume":"33","author":"de Mingo Pulido","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bneo.2025.100106_bib46","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bneo.2025.100106_bib47","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.bneo.2025.100106_bib48","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100106_bib49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/bjh.17461","article-title":"Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies","volume":"193","author":"Moskorz","year":"2021","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.bneo.2025.100106_bib50","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.bneo.2025.100106_bib51","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.bneo.2025.100106_bib52","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.4049\/jimmunol.1900328","article-title":"Bone marrow monocytes and derived dendritic cells from myelodysplastic patients have functional abnormalities associated with defective response to bacterial infection","volume":"204","author":"Bento","year":"2020","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100106_bib53","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.leukres.2015.06.007","article-title":"Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia","volume":"39","author":"Fozza","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.bneo.2025.100106_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.659625","article-title":"Response to hypomethylating agents in myelodysplastic syndrome is associated with emergence of novel TCR clonotypes","volume":"12","author":"Abbas","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100106_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3324\/haematol.2020.268136","article-title":"Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes","volume":"107","author":"Van Leeuwen-Kerkhoff","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bneo.2025.100106_bib56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","article-title":"Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity","volume":"177","author":"Binnewies","year":"2019","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bneo.2025.100106_bib57","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1078-0432.CCR-22-2601","article-title":"Immunologic predictors for clinical responses during immune checkpoint blockade in patients with myelodysplastic syndromes","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.bneo.2025.100106_bib58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.2023023166","article-title":"T-cell dysfunctions in myelodysplastic syndromes","volume":"143","author":"Rodriguez-Sevilla","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100106_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100654","article-title":"BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting","volume":"43","author":"Przespolewski","year":"2020","journal-title":"Blood Rev"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802500041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802500041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:14Z","timestamp":1778938634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032802500041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S295032802500041X"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100106","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Checkpoint immunotherapy is associated with preferential activation of tumor antigen\u2013specific CD4+ T cells in MDS","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":".","name":"copyright","label":"Copyright"}],"article-number":"100106"}}